TP53 and acute myeloid leukemia: In the second hierarchical position are Tumor Protein (TP)53 mutations (if variant allele frequency [VAF] ≥ 10%), which define a new type of pathology intermediate between acute leukemia and myelodysplastic syndrome (MDS/AML) if blasts are between 10 and 19%, and AML if blasts are ≥20%.